Humedix

What Humedix does

Humedix (주)휴메딕스 is a KOSDAQ-listed South Korean healthcare company and majority-owned subsidiary of Huons Global, operating across four business segments: aesthetic injectables (hyaluronic acid fillers, ECM boosters), ethical pharmaceuticals (osteoarthritis injectables, PDRN injectables), derma cosmeceuticals (Elravie brand), and pharmaceutical raw materials including high-purity hyaluronic acid, PDRN, and heparin sodium API. The company's core technology platforms include proprietary high-purity hyaluronic acid production meeting US, European, and Japanese pharmacopeia standards, cell-free allogeneic dermis (hADM) processing — a first in Korea applied to the Re2O ECM booster line — and HiVE/Hi-B crosslinking methods that minimize BDDE residue while achieving high viscoelasticity. Other proprietary capabilities include PDRN extraction from salmon DNA, plant-derived exosome technology, and exclusive in-licensing of the VEGF antibody patent (KR-1093717) from the Korea Institute of Biotechnology.

The company operates a cGMP-grade Factory 2 in Jecheon Bio Valley with annual capacity of 100 million ampules, 50 million vials, 20 million pre-filled syringes, and 10 million fillers — approximately four times the size of Factory 1. Revenue is generated through multiple channels: direct B2B sales to dermatology and plastic surgery clinics in Korea, TV home shopping and e-commerce for consumer derma cosmetics under the Elravie brand, contract manufacturing (CMO) services for ophthalmic solutions and injectables, and international export to 20+ countries via regional distributors across China, Taiwan, Southeast Asia, Brazil, Russia, the Middle East, and Europe. Reported 2023 revenue was 1,523 billion KRW with 24% year-over-year growth and operating profit up 43% to 373 billion KRW; Q1 and Q2 2024 revenue continued at 14-15% year-over-year growth, reaching 412 and 459 billion KRW respectively. Customer concentration is diversified across medical aesthetic institutions, orthopedic patients, derma cosmetic consumers, and pharmaceutical CMO partners, though the parent Huons Group relationship creates structural intercompany revenue. Recent strategic moves include a 50 billion KRW strategic investment in EnsolBioScience for osteoarthritis peptide treatment rights, China NMPA approval for the Riporia HARA-L filler, Korea's first domestic heparin sodium API registration, and an active treasury buyback program reflecting strong cash generation.

Name

Humedix

Legal name

(주)휴메딕스

Website

https://humedix.com

Company type

Public

Founded year

2003

Operating status

Operating

Headcount range

101–250 employees

Short description

Humedix is a KOSDAQ-listed South Korean biopharmaceutical subsidiary of Huons Global that develops and manufactures hyaluronic acid fillers, ECM boosters, osteoarthritis injectables, derma cosmeceuticals, and pharmaceutical APIs (HA, PDRN, heparin sodium), serving medical aesthetic clinics, orthopedic patients, and pharmaceutical partners across 20+ countries.

Ownership category

akta.pro rank

Product category

Medical Aesthetics Pharmaceuticals

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841), Perfumes, Cosmetics & Other Toilet Preparations (2844), Industrial Organic Chemicals (2860)

akta.pro primary industry

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

akta.pro secondary industries

Dermocosmetics & Medical-Grade Skincare (CRABAAAF), Professional/Backbar Skincare (Esthetician & Spa Use) (CRABAAAK)

Keywords

• Hyaluronic acid fillers
• Derma cosmeceuticals
• Medical aesthetics products
• Pharmaceutical contract manufacturing
• Osteoarthritis injections

Headquarters

HQ city

Seongnam

HQ country

South Korea

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Infrastructure, Operations, Personnel, Marketing or Sales

Revenue model

1. Aesthetic Products (Fillers, ECM, Cosmetics): Revenue from hyaluronic acid fillers (Elravie Premier, Riporia), ECM boosters (Re2O, Re2O Fine), and derma cosmetics (Elravie Cosmetic). Sold through medical institutions and direct-to-consumer channels.
2. CMO (Contract Manufacturing): Contract manufacturing services for pharmaceuticals including ophthalmic solutions, specialized pharmaceuticals, and injectable products using cGMP facilities.
3. Pharmaceutical Raw Materials: Production and sales of raw pharmaceutical materials including hyaluronic acid, PDRN, and heparin sodium for other pharmaceutical companies.
4. Osteoarthritis Treatment Products: Sales of injectable osteoarthritis treatments including HUMIA (single-injection, 6-month efficacy) and HyHyal Plus (3-injection formulation). Sold through medical institutions domestically and via export.
5. International Export: Export revenue from fillers, cosmetics, and pharmaceuticals to China, Southeast Asia, Brazil, Russia, Middle East, Europe through distribution partners and direct export.

Pricing tiers

Go-to-market motion4 records

Distribution channels7 records

Marketing channels7 records

Core offering

Humedix manufactures and sells hyaluronic acid-based medical aesthetic products including dermal fillers, ECM boosters, osteoarthritis injections, and derma cosmetics, along with related medical devices (Dermashine, Derma Atom) and pharmaceutical raw materials (HA, PDRN, heparin sodium). The company also offers cGMP-grade contract manufacturing services for injectables and ophthalmic solutions, and exports products through international distributors across Asia, Europe, Latin America, and the Middle East.

Product overview

Humedix is a diversified healthcare company organized into four main business segments: medical devices (dermal fillers, aesthetic equipment), cosmetics (derma cosmeceuticals under the Elravie brand), ethical pharmaceuticals (osteoarthritis injectables, PDRN injectables), and pharmaceutical raw materials (HA, PDRN, heparin sodium). The core product portfolio centers on the Elravie Premier hyaluronic acid filler brand, the Re2O/Re2O Fine ECM booster line, and the Humia sustained-release osteoarthritis injection. These are complemented by the Elravie derma cosmetics sub-brand (skincare, sunscreen, ampoules, masks), the Derma Shine/Derma Atom aesthetic device line, and pharmaceutical APIs including PDRN, HA, and heparin sodium. Recent additions include Liporia HARA-L filler (China NMPA approved), the RF device Dermashine Duo RF, wound dressing Arke, and the plant-exosome product Izment. The company operates a cGMP-grade second factory in Jecheon, Korea.

Differentiator

Problem solved

Functional benefit

Brands

• 엘라비에 (Elravie): Hyaluronic acid filler brand including Elravie Premier, Elravie Balance, and Elravie Soft. Also includes derma cosmeceutical line with ampoules, masks, cushion, and sunscreen products.
• 리투오 (Re2O)
• 이즈먼트 (Easment)
• 더마샤인 (Dermashine)
• 휴미아 (Humia)
• 리비탈렉스 (Rivitalex)
• 휴더마 (Huderma)
• 리에이此 (Lipoid HARA)

Products and services

• Elravie Premier Filler Premium crosslinked hyaluronic acid dermal filler developed using Humedix's proprietary high-purity, fixed-dose HA raw material technology and Hi-B (High Viscoelasticity-Hybrid) crosslinking method. Sold to dermatology clinics and plastic surgery hospitals for aesthetic injection procedures.
• Liporia HARA-L Premium crosslinked HA dermal filler leveraging Humedix's HiVE crosslinking technology to maximize advantages of both monophasic and biphasic filler technologies. For distribution to Chinese aesthetic medical institutions.
• Rivoline HA Filler Crosslinked hyaluronic acid dermal filler brand for aesthetic use, sold to medical institutions.
• Humia Osteoarthritis Injection Single-injection sustained-release osteoarthritis treatment providing 6 months of efficacy. Developed using Humedix's proprietary biopolymer application and high-purity HA production technology. Approved in Korea, Europe (CE), and Taiwan (TFDA). Sold to medical institutions for intra-articular injection in knee osteoarthritis patients.
• Hyohyal Plus Injection 3-injection regimen HA-based osteoarthritis treatment. Sold through medical institutions domestically and via export.
• Libitaleksu PDRN Injection PDRN (Polydeoxyribonucleotide sodium) injection drug using salmon milt-derived PDRN from Russian pristine regions. Available as standard injection and pre-filled syringe for skin grafting wound healing and tissue repair. Sold to medical institutions.
• Letotalke Injection PDRN-based injection product for regenerative medicine and aesthetic applications. Sold to medical institutions.
• Re2O ECM Booster Acellular homologous dermis (hADM)-based ECM (Extracellular Matrix) booster product. Re2O Fine is a refined version with smaller particle size for precision application in under-eye and neck areas. Korea's first application of cell-free hADM technology. Sold to medical aesthetic professionals.
• Dermashine Balance Automated pressure-sensing injection system medical device for hyaluronic acid skin boosters. Uses 32G 9-pin sterilized injection needles optimized for water-bright injection procedures. CE marked for European market. Sold to dermatology clinics and medical aesthetic institutions.
• Dermashine Pro Third-generation automated pressure-sensing injection system for skin boosting procedures. CE marked for European market. Manufactured by subsidiary Panasi and sold to medical aesthetic institutions.
• Dermashine Duo RF Radio Frequency (RF) medical device for dermatology and aesthetic skin treatments. Sold to dermatology clinics as part of Humedix's integrated aesthetic portfolio combining fillers, ECM boosters, and devices.
• Derma Akne Combination medical device for acne treatment composed of pulsed light irradiator (Class 3), high-frequency stimulator (Class 3), and electrosurgical unit (Class 3). First combination medical device of its kind in Korea. Sold to dermatology clinics.
• Derma Atom Class 2 medical device for drug absorption-enhancing skin stimulation. Features a 64-pin dedicated needle with vial attachment for convenient and fast application. Sold to dermatology and aesthetic clinics in Korea via GCS distribution agreement.
• Elravie Derma Cosmetics Derma cosmeceutical brand leveraging pharmaceutical-grade formulation expertise and HA technology. Product lineup includes Melariton Sun Serum, Melariton Melasma Cushion, Atopeiron Calm Cream, Elravie Pro Line, Ampoule Duo, and Derma Elravie Mask line. Sold direct-to-consumer through Lotte Home Shopping, official websites, and Naver Smart Store.
• Izment (EASMENT) Plant Exosome Skincare Plant-derived exosome-based cosmeceutical skin booster for clinic use. Izment T uses tomato callus-derived exosomes for whitening/soothing/moisturizing; Izment G uses Lithospermum callus-derived exosomes for pore improvement and skin barrier regeneration. Sold to dermatology clinics for use alongside aesthetic procedures.
• Pharmaceutical Contract Manufacturing (CMO) Contract manufacturing services for pharmaceuticals including ophthalmic solutions, specialized pharmaceuticals, and injectable products using cGMP-certified facilities. Includes participation in Sputnik V COVID-19 vaccine CMO consortium (2021) for vial filling and final packaging.
• Heparin Sodium API Active pharmaceutical ingredient for anticoagulation. First domestically produced heparin sodium in Korea using Humedix's proprietary purification technology. Sold to pharmaceutical companies as raw material.
• Hyaluronic Acid Raw Material High-purity hyaluronic acid raw material meeting US, European, and Japanese pharmacopeia standards. Core input material for fillers, osteoarthritis injectables, and cosmeceutical products. Sold to other pharmaceutical companies.
• Arke Wound Dressing Point-adhesion transparent wound dressing for skin barrier protection, used on damaged skin areas including first-degree burns and dry skin. Distributed domestically through exclusive partnership with Wonbiogen.

Quantifiable outcome

• Single injection of HUMIA provides 6-month efficacy for osteoarthritis treatment
• +3 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

15 partnerships are on record, tiered core and minor.

• Chengdu Shang-Li Aesthetic (샹리 에스테틱)coreChannel Partner/ Reseller/ Distributor · 19 June 2026Distribution partner for Riporia HARA-L filler in China. Humedix received China NMPA approval for the product targeting Q4 2026 launch.
• Dalian Weimisi Trading (대련 웨이미스 트레이딩)coreChannel Partner/ Reseller/ Distributor · 7 May 2024Exclusive distribution agreement for Elravie cosmetics brand in China. Dalian Weimisi Trading specializes in supplying cosmetic products to hospitals and aesthetic clinics in China.
• Woori B&B (우리비앤비)coreTechnology or Integration · 12 March 2024Supplier of pig intestinal mucosa extract for heparin sodium production. Humedix is the only domestic manufacturer with technology and facilities to produce heparin sodium raw material using proprietary purification technology.
• GCS (지씨에스)coreChannel Partner/ Reseller/ Distributor · 4 March 2024Exclusive domestic distribution agreement for 'Dermatom' drug delivery skin stimulation device. Expands medical device lineup to include automated injection pump products alongside Derma Shine and Derma Acne.
• Ensolbio (엔솔바이오)coreStrategic or Co-development Partner · 26 July 2023Exclusive domestic sales rights agreement for osteoarthritis treatment E1K (Engedi1000). Humedix will handle domestic sales while Ensolbio receives milestone payments of 80 billion KRW plus royalties on sales. Product targeted for 2027 market launch.
• Ensolbio (엔솔바이오)coreStrategic or Co-development Partner · 20 February 2023Strategic equity investment of 50 billion KRW for 5.08% stake in Ensolbio. Humedix secured domestic exclusive sales rights for osteoarthritis treatment E1K (Engedi1000) in development. Ensolbio is developing peptide-based drugs including osteoarthritis treatment, degenerative disc treatment, and anticancer therapies.
• G2J Bio/Corea Pharma (지투지바이오·한국파마)minorStrategic or Co-development Partner · 4 October 2022Joint development of once-monthly injectable Alzheimer's treatment (GB-5001) using donepezil. G2J Bio provides InnoLAMP sustained-release technology, Humedix and Korea Pharma handle clinical trials, approval, and sales with domestic rights.
• Wonbiogen (원바이오젠)minorChannel Partner/ Reseller/ Distributor · 19 September 2022Exclusive domestic sales rights for 'Kiriel' adhesive transparent wound dressing. Partnership also includes collaboration on new product development using wound dressing technology for skin aesthetics applications.
• Epibiotek (에피바이오텍)minorStrategic or Co-development Partner · 6 September 2022MOU for joint development of hair loss treatment. Combines Humedix's injection manufacturing expertise with Epibiotek's hair follicle cell technology platforms including stem cell isolation/culture and organoid-based differentiation.
• Aribio (아리바이오)minorStrategic or Co-development Partner · 16 May 2018Strategic partnership for joint R&D and production of cosmetic products. Humedix to outsource cosmetics manufacturing to Aribio while sharing technology and developing new products together.
• Huons (휴온스)coreChannel Partner/ Reseller/ Distributor · 24 April 2018Exclusive supply and sales agreement for PDRN injectable products (Livitalex). Humedix supplies products exclusively to Huons which holds exclusive sales rights for regenerative medicine market entry.
• Beijing Interims (베이징 인터림스)coreChannel Partner/ Reseller/ Distributor · 26 March 2018Distribution partner for Elravie filler in Beijing and Chongqing regions of China. Organized facility tours for Chinese dermatologists and plastic surgeons.
• Panace (파나시)coreOthers · 1 October 2017Subsidiary specializing in medical aesthetics devices. Manufactures Derma Shine series, Derma Acne, and other aesthetic medical equipment. Humedix acquired Panace in 2016.
• PMI (Indonesia)coreChannel Partner/ Reseller/ Distributor · 1 January 2016Exclusive supply agreement for Elravie filler in Indonesia valued at 780 million USD over 5 years. PMI operates hospitals under ERHA Clinic brand across Indonesia.
• Korea Institute of Biotechnology (한국생명공학研究院)coreTechnology or Integration · 1 January 2012Exclusive licensing of VEGF antibody patent (KR-1093717) for domestic and international development of macular degeneration treatments, cancer, arthritis, psoriasis, and diagnostic products.

Scale indicators11 records

Recent moves6 records

Expansion highlights8 records

Peers

• Merz Aesthetics:

Broad incumbents

• Galderma: Global dermatology and aesthetics company with HA filler (Restylane) and broader skincare portfolio. Head-to-head competitor in CE- and NMPA-approved aesthetic markets alongside Humedix.
• AbbVie (Allergan Aesthetics): Global filler leader (Juvederm) and aesthetics incumbent. Competes with Humedix in premium HA filler category worldwide; benchmark for viscoelasticity technology and pricing tiers.
• LG Chem (Life Sciences): Korean conglomerate with life-sciences aesthetics business including HA fillers and botulinum toxin. Direct domestic competitor with greater parent-company resources for international expansion.

Direct peers

• Hugel: Korean aesthetics company and closest domestic competitor to Humedix, with leading botulinum toxin (Botulax) and hyaluronic acid filler (The Chaeum) franchises. Directly competes in Korean dermatology channels and in CE/NMPA export markets.
• Medytox: Korean aesthetics peer competing in botulinum toxin (Meditoxin/Neuronox) and fillers. Direct competitor for Korean KOL share and Asian export markets overlapping with Humedix's Elravie and Riporia franchises.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UC211PAceLoNC5QZNb4nuKWw
• Facebookfacebook.com/huons
• LinkedInlinkedin.com/company/humedix-co-ltd

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Humedix